[1]El-SERAG HB.Epidemiology of viral hepatitis and hepatocellular carcinoma[J].Gastroenterology, 2012, 142 (6) :1264-1273, e1.
|
[2]CHEN W, ZHENG R, BAADE PD, et al.Cancer statistics in China, 2015[J].CA Cancer J Clin, 2016, 66 (2) :115-132.
|
[3]MUKHERJEE B, BHATTACHARYA S, CHAKRABORTY S, et al.Is type 2 diabetes mellitus a predisposal cause for developing hepatocellular carcinoma?[J].Curr Diabetes Rev, 2015, 11 (2) :64-70.
|
[4]SHAW JE, SICREE RA, ZIMMET PZ.Global estimates of the prevalence of diabetes for 2010 and 2030[J].Diabetes Res Clin Pract, 2010, 87 (1) :4-14.
|
[5]OKANOUE T, UMEMURA A, YASUI K, et al.Nonalcoholic fatty liver disease and nonalcoholic steatohepatitis in Japan[J].J Gastroenterol Hepatol, 2011, 26 (Suppl 1) :153-162.
|
[6]GIOVANNUCCI E, HARLAN DM, ARCHER MC, et al.Diabetes and cancer:a consensus report[J].Diabetes Care, 2010, 33 (7) :1674-1685.
|
[7]YANG WS, VA P, BRAY F, et al.The role of pre-existing diabetes mellitus on hepatocellular carcinoma occurrence and prognosis:a meta-analysis of prospective cohort studies[J].PLo S One, 2011, 6 (12) :e27326.
|
[8]WANG C, WANG X, GONG G, et al.Increased risk of hepatocellular carcinoma in patients with diabetes mellitus:a systematic review and meta-analysis of cohort studies[J].Int J Cancer, 2012, 130 (7) :1639-1648.
|
[9]SCHLESINGER S, ALEKSANDROVA K, PISCHON T, et al.Diabetes mellitus, insulin treatment, diabetes duration, and risk of biliary tract cancer and hepatocellular carcinoma in a European cohort[J].Ann Oncol, 2013, 24 (9) :2449-2455.
|
[10]SETIAWAN VW, HERNANDEZ BY, LU SC, et al.Diabetes and racial/ethnic differences in hepatocellular carcinoma risk:the multiethnic cohort[J].J Natl Cancer Inst, 2014, 106 (12) :dju326.
|
[11]YANG JD, AHMED MOHAMMED H, CVINAR JL, et al.Diabetes mellitus heightens the risk of hepatocellular carcinoma except in patients with hepatitis C cirrhosis[J].Am J Gastroenterol, 2016, 111 (11) :1573-1580.
|
[12]LI CI, CHEN HJ, LAI HC, et al.Hyperglycemia and chronic liver diseases on risk of hepatocellular carcinoma in Chinese patients with type 2 diabetes—National cohort of Taiwan diabetes study[J].Int J Cancer, 2015, 136 (11) :2668-2679.
|
[13]WANG YG, WANG P, WANG B, et al.Diabetes mellitus and poorer prognosis in hepatocellular carcinoma:a systematic review and metaanalysis[J].PLo S One, 2014, 9 (5) :e95485.
|
[14]ALEMN JO, EUSEBI LH, RICCIARDIELLO L, et al.Mechanisms of obesity-induced gastrointestinal neoplasia[J].Gastroenterology, 2014, 146 (2) :357-373.
|
[15]VANNI E, BUGIANESI E.Obesity and liver cancer[J].Clin Liver Dis, 2014, 18 (1) :191-203.
|
[16]CHEN Y, WANG X, WANG J, et al.Excess body weight and the risk of primary liver cancer:an updated meta-analysis of prospective studies[J].Eur J Cancer, 2012, 48 (14) :2137-2145.
|
[17]LIU X, XU J.Body mass index and waistline are predictors of survival for hepatocellular carcinoma after hepatectomy[J].Med Sci Monit, 2015, 21:2203-2209.
|
[18]VOHRA NA, KACHARE SD, VOS P, et al.The short-term effect of weight loss surgery on volumetric breast density and fibroglandular volume[J].Obes Surg, 2016.[Epub ahead of print]
|
[19]ASCHA MS, HANOUNEH IA, LOPEZ R, et al.The incidence and risk factors of hepatocellular carcinoma in patients with nonalcoholic steatohepatitis[J].Hepatology, 2010, 51 (6) :1972-1978.
|
[20]MEHTA SH, BRANCATI FL, SULKOWSKI MS, et al.Prevalence of type 2 diabetes mellitus among persons with hepatitis C virus infection in the United States[J].Ann Intern Med, 2000, 133 (8) :592-599.
|
[21]WONG RJ, GISH RG.Metabolic manifestations and complications associated with chronic hepatitis C virus infection[J].Gastroenterol Hepatol (N Y) , 2016, 12 (5) :293-299.
|
[22]ROMERO-GOMEZ M, FERNANDEZ-RODRIGUEZ CM, ANDRADE RJ, et al.Effect of sustained virological response to treatment on the incidence of abnormal glucose values in chronic hepatitis C[J].J Hepatol, 2008, 48 (5) :721-727.
|
[23]ARASE Y, SUZUKI F, SUZUKI Y, et al.Sustained virological response reduces incidence of onset of type 2 diabetes in chronic hepatitis C[J].Hepatology, 2009, 49 (3) :739-744.
|
[24]DYAL HK, AGUILAR M, BHUKET T, et al.Concurrent obesity, diabetes, and steatosis increase risk of advanced fibrosis among HCV patients:a systematic review[J].Dig Dis Sci, 2015, 60 (9) :2813-2824.
|
[25]DYAL HK, AGUILAR M, BARTOS G, et al.Diabetes mellitus increases risk of hepatocellular carcinoma in chronic hepatitis C virus patients:a systematic review[J].Dig Dis Sci, 2016, 61 (2) :636-645.
|
[26]MICHELOTTI GA, MACHADO MV, DIEHL AM.NAFLD, NASH and liver cancer[J].Nat Rev Gastroenterol Hepatol, 2013, 10 (11) :656-665.
|
[27]SIEGEL AB, ZHU AX.Metabolic syndrome and hepatocellular carcinoma:two growing epidemics with a potential link[J].Cancer, 2009, 115 (24) :5651-5661.
|
[28]BAFFY G, BRUNT EM, CALDWELL SH.Hepatocellular carcinoma in non-alcoholic fatty liver disease:an emerging menace[J].J Hepatol, 2012, 56 (6) :1384-1391.
|
[29]LONARDO A, BELLENTANI S, ARGO CK, et al.Epidemiological modifiers of non-alcoholic fatty liver disease:focus on high-risk groups[J].Dig Liver Dis, 2015, 47 (12) :997-1006.
|
[30]MOSCHEN AR, KASER S, TILG H.Non-alcoholic steatohepatitis:a microbiota-driven disease[J].Trends Endocrinol Metab, 2013, 24 (11) :537-545.
|
[31]SHULMAN GI.Ectopic fat in insulin resistance, dyslipidemia, and cardiometabolic disease[J].N Engl J Med, 2014, 371 (23) :1131-1141.
|
[32]SAMUEL VT, SHULMAN GI.Mechanisms for insulin resistance:common threads and missing links[J].Cell, 2012, 148 (5) :852-871.
|
[33]DONGIOVANNI P, RAMETTA R, MERONI M, et al.The role of insulin resistance in nonalcoholic steatohepatitis and liver disease development-a potential therapeutic target?[J].Expert Rev Gastroenterol Hepatol, 2016, 10 (2) :229-242.
|
[34]GARCIA-COMPEAN D, JAQUEZ-QUINTANA JO, GONZALEZGONZALEZ JA, et al.Liver cirrhosis and diabetes:risk factors, pathophysiology, clinical implications and management[J].World J Gastroenterol, 2009, 15 (3) :280-288.
|
[35]ZHANG H, PELZER AM, KIANG DT, et al.Down-regulation of type I insulin-like growth factor receptor increases sensitivity of breast cancer cells to insulin[J].Cancer Res, 2007, 67 (1) :391-397.
|
[36]MARDILOVICH K, PANKRATZ SL, SHAW LM.Expression and function of the insulin receptor substrate proteins in cancer[J].Cell Commun Signal, 2009, 7:14.
|
[37]YAO M, WANG L, YANG J, et al.IGF-I receptor as an emerging potential molecular-targeted for hepatocellular carcinoma in vitro and in vivo[J].Tumour Biol, 2016, 37 (11) :14677-14686.
|
[38]CHETTOUH H, LEQUOY M, FARTOUX L, et al.Hyperinsulinaemia and insulin signalling in the pathogenesis and the clinical course of hepatocellular carcinoma[J].Liver Int, 2015, 35 (10) :2203-2217.
|
[39]El-SERAG HB, RUDOLPH KL.Hepatocellular carcinoma:epidemiology and molecular carcinogenesis[J].Gastroenterology, 2007, 132 (7) :2557-2576.
|
[40]CAPONE F, GUERRIERO E, COLONNA G, et al.The cytokinome profile in patients with hepatocellular carcinoma and type 2 diabetes[J].PLo S One, 2015, 10 (7) :e0134594.
|
[41]NAKAGAWA H, MAEDA S, YOSHIDA H, et al.Serum IL-6levels and the risk for hepatocarcinogenesis in chronic hepatitis C patients:an analysis based on gender differences[J].Int J Cancer, 2009, 125 (10) :2264-2269.
|
[42]WONG VW, YU J, CHENG AS, et al.High serum interleukin-6level predicts future hepatocellular carcinoma development in patients with chronic hepatitis B[J].Int J Cancer, 2009, 124 (12) :2766-2770.
|
[43]PARK EJ, LEE JH, YU GY, et al.Dietary and genetic obesity promote liver inflammation and tumorigenesis by enhancing IL-6 and TNF expression[J].Cell, 2010, 140 (2) :197-208.
|
[44]ALI KAMKAR MM, AHMAD R, ALSMADI O, et al.Insight into the impact of diabetes mellitus on the increased risk of hepatocellular carcinoma:mini-review[J].J Diabetes Metab Disord, 2014, 13:57.
|
[45]NAUGLER WE, SAKURAI T, KIM S, et al.Gender disparity in liver cancer due to sex differences in My D88-dependent IL-6 production[J].Science, 2007, 317 (5834) :121-124.
|
[46]YU H, PARDOLL D, JOVE R.STATs in cancer inflammation and immunity:a leading role for STAT3[J].Nat Rev Cancer, 2009, 9 (11) :798-809.
|
[47]HE G, YU GY, TEMKIN V, et al.Hepatocyte IKKbeta/NF-kappa B inhibits tumor promotion and progression by preventing oxidative stress-driven STAT3 activation[J].Cancer Cell, 2010, 17 (3) :286-297.
|
[48]TAKAHASHI H, MIZUTA T, EGUCHI Y, et al.Post-challenge hyperglycemia is a significant risk factor for the development of hepatocellular carcinoma in patients with chronic hepatitis C[J].J Gastroenterol, 2011, 46 (6) :790-798.
|
[49]MILES KA, WILLIAMS RE.Warburg revisited:imaging tumour blood flow and metabolism[J].Cancer Imaging, 2008, 8:81-86.
|
[50]CHOCARRO-CALVO A, GARCIA-MARTINEZ JM, ARDILAGONZALEZ S, et al.Glucose-induced beta-catenin acetylation enhances Wnt signaling in cancer[J].Mol Cell, 2013, 49 (3) :474-486.
|
[51]EVANS JM, DONNELLY LA, EMSLIE-SMITH AM, et al.Metformin and reduced risk of cancer in diabetic patients[J].BMJ, 2005, 330 (7503) :1304-1305.
|
[52]BOWKER SL, MAJUMDAR SR, VEUGELERS P, et al.Increased cancer-related mortality for patients with type 2 diabetes who use sulfonylureas or insulin:response to farooki and schneider[J].Diabetes Care, 2006, 29 (8) :1990-1991.
|
[53]HASSAN MM, CURLEY SA, LI D, et al.Association of diabetes duration and diabetes treatment with the risk of hepatocellular carcinoma[J].Cancer, 2010, 116 (8) :1938-1946.
|
[54]STEVENS RJ, ALI R, BANKHEAD CR, et al.Cancer outcomes and all-cause mortality in adults allocated to metformin:systematic review and collaborative meta-analysis of randomised clinical trials[J].Diabetologia, 2012, 55 (10) :2593-2603.
|
[55]SUN G, KASHYAP SR.Cancer risk in type 2 diabetes mellitus:metabolic links and therapeutic considerations[J].J Nutr Metab, 2011, 2011:708183.
|
[56]GIOVANNUCCI E, HARLAN DM, ARCHER MC, et al.Diabetes and cancer:a consensus report[J].CA Cancer J Clin, 2010, 60 (4) :207-221.
|
[57]FUJITA K, IWAMA H, MIYOSHI H, et al.Diabetes mellitus and metformin in hepatocellular carcinoma[J].World J Gastroenterol, 2016, 22 (27) :6100-6113.
|